aTYR PHARMA (ATYR) Revenue (2019 - 2025)

aTYR PHARMA's (ATYR) quarterly Revenue came in at $190000.0 in Q3 2025, down 19.15% quarter-over-quarter from $235000.0 in Q1 2024.

Analysis

aTYR PHARMA (ATYR) Revenue (2019 - 2025) Analysis & Trends

aTYR PHARMA (ATYR) has reported Revenue for 6 consecutive years, with $190000.0 the latest figure, recorded in Q3 2025.

For the quarter ending Q3 2025, Revenue changed N/A year-over-year to $190000.0; the trailing twelve-month figure through Mar 2026 stood at $190000.0 (changed N/A YoY), and the FY2025 full-year result was $190000.0, down 19.15% from the prior year.
Revenue fell to $190000.0 in Q3 2025 per ATYR's latest filing, from $235000.0 in the prior quarter.
Across five years, Revenue topped out at $10.4 million in Q4 2022 and bottomed at $190000.0 in Q3 2025.
Historically, Revenue has averaged $2.8 million across 4 years, with a median of $294000.0 in 2023.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Amgen	208.48 Bn	194.49 Bn	7.24 Bn	10.05 Bn
2	Gilead Sciences	186.29 Bn	183.02 Bn	6.22 Bn	7.80 Bn
3	Vertex Pharmaceuticals	128.79 Bn	120.93 Bn	2.84 Bn	3.33 Bn
4	Regeneron Pharmaceuticals	80.66 Bn	72.67 Bn	3.93 Bn	4.29 Bn
5	Moderna	61.46 Bn	56.32 Bn	52.00 Mn	145.00 Mn
6	Argenx Se	61.28 Bn	56.10 Bn	1.37 Bn	1.52 Bn
7	Alnylam Pharmaceuticals	32.04 Bn	28.73 Bn	992.69 Mn	1.29 Bn
8	Biogen	31.84 Bn	30.56 Bn	1.96 Bn	2.74 Bn
9	Roivant Sciences	28.74 Bn	29.43 Bn	1.16 Mn	1.44 Mn
10	aTYR PHARMA	35.31 Mn	-22.30 Mn	-	-

Historic Data

Download Data